找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Urologic Oncology; Multidisciplinary Ca Kelly L. Stratton,Alicia K. Morgans Book 2022 The Editor(s) (if applicable) and The Author(s), unde

[復(fù)制鏈接]
樓主: dabble
21#
發(fā)表于 2025-3-25 04:25:18 | 只看該作者
Book 2022ngly integrates radiation therapy to primary cancers, nodal beds, and even metastatic sites. The culmination of these advances has been the creation of multidisciplinary teams that expertly provide comprehensive care to patients with urologic cancers. This book provides the framework to create such
22#
發(fā)表于 2025-3-25 11:31:06 | 只看該作者
High-Risk Localized Prostate Cancer,egies including surgery, radiation, and systemic therapy to ensure the best care in a rapidly evolving field. In this chapter we will review treatment of high-risk localized prostate cancer emphasizing the major pieces of evidence which underlie high-risk prostate cancer management.
23#
發(fā)表于 2025-3-25 15:18:30 | 只看該作者
24#
發(fā)表于 2025-3-25 17:24:40 | 只看該作者
25#
發(fā)表于 2025-3-25 20:44:19 | 只看該作者
Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer,literature describing oncologic outcomes, discussion of quality of life considerations, and description of treatment planning techniques for high-quality radiotherapy (RT) delivery. Ongoing randomized clinical trials (RCTs) of interest will be underscored throughout as they pertain to each aspect of treatment.
26#
發(fā)表于 2025-3-26 01:38:57 | 只看該作者
Creating a Multidisciplinary Clinic,ng this care model can be challenging as it requires significant administrative support and a substantial commitment from the participating physicians. This chapter is a guide for those starting a MDC of their own.
27#
發(fā)表于 2025-3-26 04:18:54 | 只看該作者
28#
發(fā)表于 2025-3-26 11:35:34 | 只看該作者
Immunotherapy for Metastatic Prostate Cancer,xicity remains an important consideration for all the work conducted so far. As more work is done to optimize immunotherapy in prostate cancer, future studies may need to extend their scope to immune cells outside of the T cell and perhaps beyond checkpoint inhibition.
29#
發(fā)表于 2025-3-26 12:44:02 | 只看該作者
30#
發(fā)表于 2025-3-26 17:46:27 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-18 02:54
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
揭东县| 黔江区| 莱西市| 旺苍县| 梨树县| 尼玛县| 榕江县| 梓潼县| 奎屯市| 增城市| 虹口区| 汝南县| 藁城市| 休宁县| 镇康县| 武功县| 周宁县| 甘孜县| 商丘市| 蓬莱市| 永城市| 蓬安县| 北流市| 始兴县| 榕江县| 定结县| 镇原县| 丰城市| 福清市| 林甸县| 台北市| 六枝特区| 天祝| 永修县| 上饶县| 宁蒗| 沙湾县| 贵溪市| 铜川市| 株洲县| 朝阳县|